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Background
Tuberculous meningitis (TBM), an infectious disease of the central nervous system 
(CNS), has been on the rise in recent years worldwide, especially in developing coun-
tries (Mastroianni et al. 1997). About 30 % of TBM patients die despite anti-TB chemo-
therapy, mainly due to delayed diagnosis or treatment (Thwaites et al. 2000). The clinical 
diagnosis of TBM is often difficult because of the complexity of the clinical manifesta-
tions and difficulty in differentiating TBM (Kashyap et al. 2001). Currently, the diagnosis 
of TBM is mainly based on cerebrospinal fluid (CSF) analysis, but both sensitivity and 
specificity are low, and it is time consuming. It is therefore necessary to find a more sen-
sitive and specific biomarker for quick diagnosis or exclude TBM.
Abstract 
Purpose: High mobility group box-1 (HMGB1) is a proinflammatory, DAMP protein 
that participates in many pathological conditions. In this study, we evaluated the usa-
bility of CSF HMGB1 as a biomarker for the diagnosis of tuberculous meningitis (TBM).
Methods: A total of 59 TBM patients and 169 control patients were included in our 
study. CSF samples were obtained and analyzed for HMGB1 using a commercial ELISA 
kit.
Results: The mean CSF HMGB1 was 19.36 ng/ml in TBM patients (n = 59) versus 
3.12 ng/ml in non-TB meningitis patients (n = 30), 2.13 ng/ml in patients with extra 
neural tuberculosis (n = 73), and 1.06 ng/m in controls (n = 66). According to the 
receiver operator characteristic curves, a cut-off value of 3.4 ng/ml was calculated, indi-
cating that the sensitivity and specificity of CSF HMGB1 alone in diagnosis of TBM were 
61.02 and 89.94 %, respectively. In patients with extra neural tuberculosis and a high 
risk of TBM, CSF HMGB1 seemed to be a good candidate for early differential diagnosis 
of TBM at the cut-off value of 3.8 ng/ml, when the sensitivity and specificity were 79.49 
and 94.52 % respectively.
Conclusion: Our finding may prove to be clinically useful, because CSF HMGB1 ELISA 
can be performed in almost all clinical laboratories, especially when sophisticated tech-
nologies are either time consuming or unavailable.
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High mobility group box-1(HMGB1) is non-histone nuclear DNA-binding protein 
ubiquitously expressed in all mammalian cells that plays a vital role in the nuclei of all 
eukaryotic cells (Lotze and Tracey 2005). HMGB1 protein is considered to be a dam-
age-associated molecular patterns (DAMP) signal in inflammatory conditions (He et al. 
2013; Qin et  al. 2009, 2014; Scaffidi et  al. 2002), tumors (Chung et  al. 2009; Lee et  al. 
2012), and nutritional deficiencies (Ruan et  al. 2014; Rickenbacher et  al. 2014). Many 
studies have demonstrated that HMGB1 is a candidate diagnostic marker in diseases 
such as rheumatoid arthritis (Schierbeck et al. 2013; Kyostio-Moore et al. 2011), inflam-
matory bowel disease (Palone et al. 2014; Vitali et al. 2011), and sleep apnea syndrome 
(Wu et al. 2010). So it is reasonable to speculate that HMGB1 level in CSF will increase 
when CNS was invaded by M. tuberculosis.
In the present study, we hypothesize that CSF HMGB1 levels could be a good bio-
marker to aid in TBM diagnosis, as well as a good candidate to aid in differential diag-
nosis among TBM high-risk patients. The aim of this study was therefore to evaluate the 
diagnostic value, sensitivity, and specificity of CSF HMGB1 in TBM patients.
Methods
Ethics statement
Our research was approved by the Research Ethics Committee of ChangHai Hospital 
and Shanghai Pulmonary Disease Hospital. All participants gave informed written con-
sent. All procedures were carried out in accordance with Ethical Guidelines for Biomed-
ical Research Involving Human Subjects of Changhai Hospital. All the data in this study 
were anonymised.
Study participants
Our study involved 228 patients who were admitted in ChangHai Hospital or Shanghai 
Pulmonary Disease Hospital between January 2011 and December 2012. The patients 
fell into four groups: TBM group (n = 59), non-TB meningitis group (meningitis caused 
by other pathogens) (n = 30), extra neural tuberculosis group (pulmonary, intestinal, or 
joint tuberculosis) (n = 73), and control group (n = 66).
Diagnostic criteria of TBM
The diagnostic criteria for TBM were according to Ahuja et al. (1994) as follows:
A. Clinical manifestations: Fever and headache lasting for more than 14 days (manda-
tory), in addition to vomiting, altered sensorium or the presence of focal deficits 
(optional).
B. CSF: Pleocytosis with more than 20 cells; predominantly (greater than 60  %) lym-
phocytes; protein greater than 1 g/l; sugar less than 60 % of the corresponding blood 
sugar; and negative India ink study and cytology for malignant cells (in relevant situ-
ations).
C. Radiological findings: head CT scan showing two or more of the following: ① exu-
dates in basal cisterns or Sylvian fissures; ② hydrocephalus; ③ infarcts; and ④ gyral 
enhancement.
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D. Extra neural tuberculosis: Active tuberculosis of the lung, gastrointestinal tract, 
urogenital tract, lymph nodes, skeletal system or skin as evidenced by appropriate 
radiological or microbiological tests or by the presence of caseation necrosis on his-
topathological examination.
The 4 sub-criteria described above were incorporated into the four groups in a 
descending order of sensitivity in the diagnosis of TBM.
1. Definite TBM
(i) Clinical criteria (A)
(ii) Bacterial isolation from CSF (smear, culture, or TB-PCR) or diagnosis at autopsy
2. Highly probable TBM
(i) Clinical criteria (A)
(ii) All 3 of (B) and (C) and (D)
3. Probable TBM
(i) Clinical criteria (A)
(ii) Any 2 of B, C and D
4. Possible TBM
(i) Clinical criteria (A)
(ii) Any one of (B) (C) and (D)
In this study, definite, highly probable, and probable TBM were considered as TBM, 
while possible TBM were considered as non-TB meningitis or extra neural tuberculosis.
CSF processing
CSF samples were centrifuged immediately at 1300×g for 10 min, and the supernatant 
was stored at −80 °C in a 1.5 ml microcentrifuge tube prior to analysis for HMGB1.
Measurement of CSF HMGB1 levels
The concentration of HMGB1 was measured by the commercially available HMGB1 
ELISA Kit II (SHINO-TEST Corporations, Kanagawa, Japan) according to the manufac-
turer’s instructions. Briefly, 100 μl sample diluent was added to each well, and then 10 μl 
standard, sample or control was added to the well. The microtiter plate was incubated 
for 20–24 h at 37 °C. After washing, 100 μl/well of anti-humanHMGB1 peroxidase-con-
jugated monoclonal antibody was added and the plate was incubated at room tempera-
ture for 2 h. After washing, the chromogen 3,3,5,5′-tetra-methylbenzidine was added to 
each well. The enzyme reaction was allowed to proceed for 30 min at room temperature. 
The chromogenic substrate reaction was terminated by addition of the stop solution 
(0.35 mol/l Na2SO4), and the absorbance was read at 450 nm. The results were calculated 
using a calibration curve prepared from standards.
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Western blotting of CSF HMGB1
A total volume of 30 μl cell free CSF sample was boiled with SDS loading buffer con-
taining protease inhibitor, separated by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE), and then transferred to the nitrocellulose membrane (Millipore, Darmstadt, 
Germany). Blots were blocked by 5  % defatted milk for 2  h, incubated with primary 
HMGB1 antibody (1:500, SaierBio, Tianjin, China), and further incubated with goat 
anti-rabbit HRP-conjugated secondary antibody (1:2000, Cell Signaling, Beverly, MA). 
The membrane was visualized with an ECL Western Blotting System (Pierce Protein 
Research Products, Rockford, IL, USA).
Statistical analysis
Statistical analysis was performed by Graphpad Prism 5.0 (Version 5.0, La Jolla, CA, 
USA). To compare the concentrations of HMGB1 in patients and controls, p values were 
calculated for the average ELISA results by one-way ANONA test and Newman-Keuls 
Multiple Comparison Test. The ROC curve was constructed for CSF HMGB1, by which 
the sensitivity, specificity, error rate and AUC were calculated to determine the diagnos-
tic accuracy of our findings.
Results
Patient demographic data
The male/female in the TBM, non-TB meningitis, extra neural tuberculosis and control 
groups was 33/26, 21/9, 40/33, and 46/20, respectively. In non-TB meningitis group, 
there are 16 viral meningitis, 9 bacterial meningitis, and 5 cryptococcal meningitis; in 
extra neural tuberculosis group, there are 68 pulmonary tuberculosis, 3 intestinal tuber-
culosis, and 2 joint tuberculosis. Patient data including age, sex and the mean level of 
HMGB1 are shown in Table 1.
HMGB1 level in diseased people and controls
The HMGB1 concentration was measured by ELISA, and results are shown in Fig. 1. The 
mean HMGB1 value in TMB group, non-TB meningitis, extra neural tuberculosis, and 
control groups was 19.36, 3.12, 2.13, and 1.06 ng/ml, respectively, showing a significant 
difference among groups (p < 0.001). Subgroup comparison CSF HMGB1 levels in TBM 
patients were significant higher than those in the other groups (p < 0.001), and there was 
no significant difference between non-TB meningitis, extra neural tuberculosis and con-
trol groups (p > 0.05). To confirm the ELISA result, CSF samples from 5 TMB patients, 
Table 1 CSF HMGB1 levels in  patients with  TBM, non-TB meningitis and  extra neural 
tuberculosis, and in control subjects
Group1: TBM patients; group 2: non-TB meningitis; group 3: Extra neural tuberculosis; group 4: control group
M male, F female, HMGB1 high mobility group box protein-1





Sex (M/F) 33/26 21/9 40/33 46/20
Age (mean, range) 32.61 (14–90) 31.09 (8 m–59) 37.05 (2–80) 47.82 (7–79)
HMGB-1 (x¯ ± sd, ng/ml) 19.36 ± 4.75 3.12 ± 2.00 2.13 ± 0.48 1.06 ± 2.17
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2 non-TB meningitis patients and 2 people were analyzed using western blotting. The 
results are shown in Fig. 2a, indicating that the intensity of the bands in TMB patients 
was higher than that in the others groups. Above all, there were 9 definite TBM cases in 
our study, and the clinical data and western blotting result were shown in Table 2 and 
Fig. 2b. The concentration of CSF HMGB1 in 9 definite TBM patients (37.50 ng/ml) was 
significant higher than the mean level of CSF HMGB1 in TBM group.
Evaluation of the sensitivity and specificity of HMGB1 for the diagnosis of TBM
The receiver operator characteristic (ROC) was evaluated with respect to sensitivity 
and specificity. The area under the curve (AUC) was 0.836. For the diagnosis of TMB, 
the best cut-off point for HMGB1 was 3.4  ng/ml, and the calculated sensitivity and 
Fig. 1 Dot plots of CSF HMGB1 in TBM, non-TB meningitis, extra neural tuberculosis, and control groups. The 
mean CSF HMGB1 was significantly higher in TBM group than others (p < 0.001)
Fig. 2 Western blotting and grayscale analysis of CSF HMGB1. a Samples from 2 controls, 2 no-TBM patients 
and 5 TBM patients; b Samples from 9 definite TBM patients. 30 μl CSF was loaded and separated by SDS-
PAGE, and HMGB1 was detected using a monoclonal anti-HMGB1 antibody. The grayscale value of protein 
bands were analyzed by ImageJ software
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specificity were 61.02 % (95 % CI 47.44–73.45 %) and 89.94 % (95 % CI 84.38–94.03 %), 
respectively (Fig. 3a).
Further investigation was performed to see whether CSF HMGB1 level could be used 
as a biomarker to help determine whether or not the CNS was involved in extra neural 
tuberculosis. As showed in Fig. 3b, at a cut-off of 3.8 ng/ml, the calculated sensitivity and 
specificity were 79.49 % (95 % CI 63.54–90.70 %) and 94.52 % (95 % CI 86.56–98.49 %), 
respectively. The positive and negative predictive value was 88.57 % (31/35) and 89.61 %, 
respectively.
Table 2 Clinical data in definite TBM patients
Case no. Year Sex Complains Lab outcome HMGB1 (pg/ml)
41 34 F Cough, fever for 1 month PCR 19.96
48 20 M Headache, dizziness for 1 month, with 
mild nuchal rigidity
PCR 68.80
51 21 F Fever, chest pain for 2 months, with 
nuchal rigidity
Acid-fast staining and PCR 51.71
60 21 F Headache for 1 month PCR 79.32
97 48 M Treated for pulmonary tuberculosis for 
7 months, complained for intermittent 
headache and malaise for 1 month
Culture 31.08
113 20 M Treated for pulmonary tuberculosis for 
7 months
Culture 23.96
132 24 F Fever for 2 months, and brain MRI shows 
multiple cerebellar tuberculoma
PCR 21.06
140 14 F Treated for pulmonary tuberculosis for 
8 months, and brain MRI shows multi-
ple tuberculoma
Culture 23.71
176 20 M Treated for pulmonary tuberculosis 
for 10 months, and brain MRI shows 
vascular lesions
PCR 17.92
Fig. 3 ROC curve of CSF HMGB1 showing the threshold value of CSF HMGB1 in the diagnosis of TBM. a CSF 
HMGB1 reached a sensitivity of 61.02 %, a specificity of 89.94 %, a positive predictive value of 67.92 %, and a 
negative predictive value of 86.86 % (cut-off value: 3.4 ng/ml; area under the curve: 0.836); b In tuberculosis 
patients, CSF HMGB1 reached a sensitivity of 79.49 %, a specificity of 94.52 %, a positive predictive value of 
88.57 %, and a negative predictive value of 89.61 % (cut-off value: 3.8 ng/ml; area under the curve: 0.888)
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Discussion
TBM infection remains a global health problem. According to the World Health Organi-
zation (WHO) report (WHO 2003), the incidence of TBM is increasing by 0.4 % every 
year worldwide, especially in developing countries. TB infection is also the major reason 
of morbidity and mortality. Delayed or no treatment will increase the risk of develop-
ing irreversible neurologic sequelae and death. The clinical diagnosis of TBM is often 
difficult due to the pleomorphic clinical presentation. Routine CSF-biochemical analy-
sis including pleocytosis with lymphocytosis may increase protein levels and reduce 
glucose levels (Thwaites et al. 2000). Despite the multiple modern diagnostic tools cur-
rently available, the diagnosis of TBM still depends primarily on the patient history 
and clinical findings. The confirmed diagnosis of TBM depends on the detection of M. 
tuberculosis from the CSF, and careful and repeated search for acid fast bacilli (AFB) by 
Ziehl-Neelsen staining or culture. Although these two methods are considered the gold 
standard for the diagnosis of TBM, the resultant yield via direct CSF staining for AFB is 
as low as 10–20 % (Bloom 1994). In addition, culture of M. tuberculosis via solid media 
such as Lowenstein-Jensen usually takes 8 weeks, often with a negative result (Thwaites 
et  al. 2002). Mycobacterial Growth Indicator Tube (MGIT)  is a liquid culture system 
developed by  Becton–Dickinson  (BD, Franklin, NJ,USA), and has a better sensitivity 
for diagnosis of TBM, but it requires special culture and detection equipment and still 
needs at least 3–4 weeks (Hannan et al. 2010; Thakur et al. 2010). Newer nucleic acid 
amplification techniques (NAAT) such as polymerase chain reaction (PCR) developed 
for the detection of M. tuberculosis in clinical specimens are more sensitive and spe-
cific but not available for widespread use in developing countries. The Xpert® MTB/RIF 
test (Cepheid, Sunnyvale, CA, USA) is an automated, cartridge-based PCR test used to 
detect M. tuberculosis in sputum, and the World Health Organization (WHO) recom-
mends it as initial TBM diagnostic test. With proper sample processing, such as cen-
trifugation, Xpert reaches a sensitivity as high as 70–80 % (Bahr et al. 2015; Patel et al. 
2013), and can detect rifampin resistance the same time. The shortcoming of Xpert is 
obvious since this test and concessional price ($9.98) are not widely available (Puri et al. 
2016). So, a rapid, easily applied and inexpensive diagnostic tool with a high diagnostic 
value for TMB is badly needed.
HMGB1 is not a new protein. It was initially named for its characteristic rapid electro-
phoretic mobility in polyacrylamide gels (Harris and Raucci 2006), as a late-phase medi-
ator of inflammation is induced by early proinflammatory cytokines. Knowing that CSF 
proteins can reflect the state of the CNS, accurate analysis of CSF should be able to pro-
vide some valuable information about the neurological health of a patient. As HMGB1 
can be actively secreted from immune cells or passively released from dying cells into 
extracellular space (Lotze and Tracey 2005), the release of HMGB1, which functions as a 
danger signal, represents a stress condition and inflammatory response to certain stimuli 
(Chung et al. 2009). A prospective observational study by Goldstein et al. (2006) showed 
that serum HMGB1 levels were elevated in patients with cerebral vascular ischemia. A 
recent study found that HMGB1 could be detected in the CSF of encephalitic dogs. We 
conclude that HMGB1 is present in the CSF of people suffering from TMB.
In this study, we investigated CSF HMGB1 levels in TB patients and evaluated the 
potential value of HMGB1 as a diagnostic biomarker. Our results showed that CSF 
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HMGB1 levels in TBM patients were elevated markedly as compared with those in the 
other control groups, especially in control subjects in whom the expression of HMGB1 
was very low or even undetectable, indicating the HMGB1 is an ideal test biomarker to 
reflect the inflammatory status of CNS. As a DAMP, CSF HMGB1 level may increase 
under certain conditions such as inflammation and ischemia. Our results suggested that 
the best cut-off value point was 3.4 ng/ml for the diagnosis of TBM, when the calculated 
sensitivity and specificity were 61.02 and 89.94 %, respectively. Although CSF HMGB1 
levels between TBM patients and control patients differed significantly, a high discrimi-
native ability was not obtained in the curve. According to by Albayrak et  al. (2011), 
whether or not the serum level of HMGB1 could be used as a diagnostic biomarker for 
the diagnosis of acute appendicitis was merely another blind alley that remained to be 
seen according to the result of ROC, which is similar to the situation in our study, where 
the sensitivity was not sensitive enough while the specificity was very good according 
to the result of HMGB1. However, because the confirmation of the diagnosis of TBM is 
very difficult and CSF HMGB1 would be helpful to identify TBM when direct smear is 
negative, PCR test isn’t available, and waiting for culture result. We further investigated 
whether CSF HMGB1 level was a good biomarker to identify TBM in patients who suf-
fered from extra neural tuberculosis such as pulmonary tuberculosis, intestinal tuber-
culosis, or joint tuberculosis. The sensitivity and specificity were 79.49  % (31/39) and 
94.52  % (69/73) respectively at a cut-off value of 3.8  ng/ml. Our results seem to sug-
gest that CSF HMGB1 level is a good diagnostic biomarker for patients with extra neu-
ral tuberculosis who have a high risk of TBM. If so, the time needed for the diagnosis 
of TBM would be much shorter and patients could receive treatment earlier. In TBM 
group, CSF HMGB1 in 9 definite TBM patients (37.50  ng/ml) was significant higher 
than highly probable, and probable TBM patients means some of the clinical diagnosis 
TBM may not accurate. Since CSF HMGB1 has high specificity, it may be a useful tool in 
helping physicians to rule out TBM.
Conclusion
In conclusion, our results showed that HMGB1 levels in the CSF of TBM patients were 
significantly higher than those in control group, non-TB meningitis, or extra neural 
tuberculosis. In addition, HMGB1 may be a helpful candidate biomarker to differenti-
ate TBM from TB in earlier stages, predict disease prognosis, or at least confirm neuro-
logical disorders in confirmed cases of TBM. However, further investigations in larger 
cohorts of individuals are needed to confirm the relevance and usefulness of HMGB1 as 
an early diagnostic marker for monitoring patients with a high risk of TBM. The possi-
bility to use HMGB1 as an early diagnosis biomarker for the detection of TB-infection in 
the CNS could avoid unnecessarily treatment and improve the outcome and prognosis 
of TBM patients.
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